Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice

Cancer Science

Volumn 101, Issue 7, 2010, Pages 1701-1707

  Yasuda, Yoichi ^a   Shimizu, Masahito ^a   Shirakami, Yohei ^a   Sakai, Hiroyasu ^a   Kubota, Masaya ^a   Hata, Kazuya ^b   Hirose, Yoshinobu ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^c   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sunplanet Co Ltd   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPOCYTOKINE; ADIPONECTIN; AZOXYMETHANE; BETA CATENIN; CHOLESTEROL; CYCLOOXYGENASE 2; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; PITAVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL MOUSE; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLON CANCER; CONTROLLED STUDY; DIET; DRUG EFFECT; FEEDING; GENE EXPRESSION; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; AZOXYMETHANE; CARCINOGENS; CELL DIVISION; COLONIC NEOPLASMS; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PRECANCEROUS CONDITIONS; QUINOLINES;

EID: 77954645899     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01579.x     Document Type: Article

References (52)

1. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132:2208-25.
2. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006, 55:285-91.
3. Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003, 46:595-607.
4. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006, 17:145-56.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
6. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-51.
7. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42:745-50.
8. Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM and DSS. Mol Med Rep 2008, 1:355-61.
9. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278:313-21.
10. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-78.
11. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-42.
12. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem 2009, 106:975-83.
13. Yasui Y, Suzuki R, Miyamoto S. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007, 121:2331-9.
14. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123:951-7.
15. Poynter JN, Gruber SB, Higgins PD. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-92.
16. Hirose Y, Hata K, Kuno T. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 2004, 25:821-5.
17. Suzuki R, Kohno H, Yasui Y. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int J Cancer 2007, 120:252-8.
18. Shimizu M, Shirakami Y, Sakai H. EGCG suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res 2008, 1:298-304.
19. Shimizu M, Shirakami Y, Iwasa J. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009, 15:3068-75.
20. Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 2007, 8:2315-27.
21. Yamada Y, Mori H. Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 2003, 24:1015-9.
22. Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000, 112-113:395-402.
23. Mori H, Yamada Y, Kuno T, Hirose Y. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat Res 2004, 566:191-208.
24. Mori H, Hata K, Yamada Y, Kuno T, Hara A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 2005, 155:1-9.
25. Tomita H, Yamada Y, Oyama T. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res 2007, 67:4079-87.
26. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
27. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004, 109:II18-26.
28. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-8.
29. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004, 58:614-8.
30. Koh KK, Quon MJ, Han SH. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009, 204:483-90.
31. Freeman DJ, Norrie J, Sattar N. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-62.
32. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30.
33. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007, 8:395-408.
34. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-94.
35. Kaklamani VG, Wisinski KB, Sadim M. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008, 300:1523-31.
36. Fujisawa T, Endo H, Tomimoto A. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008, 57:1531-8.
37. Molina A, Vendrell J, Gutierrez C. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003, 13:615-21.
38. Stattin P, Lukanova A, Biessy C. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004, 109:149-52.
39. Miyamoto S, Yasui Y, Tanaka T, Ohigashi H, Murakami A. Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. Carcinogenesis 2008, 29:1057-63.
40. Hector J, Schwarzloh B, Goehring J. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007, 39:250-5.
41. Finck BN, Johnson RW. Anti-inflammatory agents inhibit the induction of leptin by tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1429-35.
42. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-51.
43. Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev Res 2009, 2:301-9.
44. Buzzai M, Jones RG, Amaravadi RK. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67:6745-52.
45. Hwang JT, Ha J, Park IJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007, 247:115-21.
46. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008, 1:369-75.
47. Sugiyama M, Takahashi H, Hosono K. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009, 34:339-44.
48. Yamada Y, Yoshimi N, Hirose Y. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001, 61:1874-8.
49. Tan X, Hsueh W, Gonzalez-Crussi F. Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression by Paneth cells, intestinal eosinophils, and macrophages. Am J Pathol 1993, 142:1858-65.
50. Hata K, Yamada Y, Kuno T. Tumor formation is correlated with expression of beta-catenin-accumulated crypts in azoxymethane-induced colon carcinogenesis in mice. Cancer Sci 2004, 95:316-20.
51. Hirose Y, Kuno T, Yamada Y. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003, 24:107-11.
52. Kuno T, Yamada Y, Hirose Y. Induction of apoptosis by sulindac in azoxymethane-induced possible colonic premalignant lesions in rats. Jpn J Cancer Res 2002, 93:242-6.